Esperion Therapeutics Inc. (NASDAQ:ESPR) had its target price increased by Credit Suisse Group AG from $10.00 to $14.00 in a report released on Friday. The firm presently has an “underperform” rating on the biopharmaceutical company’s stock. Credit Suisse Group AG’s price objective points to a potential upside of 14.38% from the stock’s previous close.

Several other research firms have also recently commented on ESPR. JMP Securities reiterated a “buy” rating and issued a $67.00 price target on shares of Esperion Therapeutics in a research note on Thursday, June 16th. Lake Street Capital cut their price target on Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, June 29th. Royal Bank Of Canada cut Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price target for the stock from $30.00 to $15.00 in a research note on Wednesday, June 29th. JPMorgan Chase & Co. cut Esperion Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $50.00 to $15.00 in a research note on Wednesday, June 29th. Finally, Barclays PLC cut Esperion Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $28.00 to $13.00 in a research note on Wednesday, June 29th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $26.36.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Shares of Esperion Therapeutics (NASDAQ:ESPR) opened at 12.24 on Friday. Esperion Therapeutics has a 52-week low of $9.58 and a 52-week high of $30.41. The firm’s 50-day moving average price is $12.38 and its 200-day moving average price is $13.89. The firm’s market capitalization is $276.01 million.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.16. During the same period last year, the firm posted ($0.55) EPS. On average, equities analysts predict that Esperion Therapeutics will post ($3.37) earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of ESPR. Quantitative Investment Management LLC bought a new position in Esperion Therapeutics during the second quarter valued at approximately $111,000. Advisor Group Inc. acquired a new position in shares of Esperion Therapeutics during the second quarter worth about $140,000. Stifel Financial Corp raised its position in shares of Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 1,438 shares during the period. Rhumbline Advisers raised its position in shares of Esperion Therapeutics by 27.0% in the second quarter. Rhumbline Advisers now owns 17,186 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 3,657 shares during the period. Finally, ProShare Advisors LLC raised its position in shares of Esperion Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 18,533 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 238 shares during the period. 65.23% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

5 Day Chart for NASDAQ:ESPR

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.